Bispecific CD33 and CD3 binding proteins

US9803029B2 · kind B2 · utility

Assignee

• Amphivena Therapeutics, Inc. · US

Inventors

• Kristina Ellwanger · Heidelberg, DE
• Luke Evnin · San Francisco, US
• Judith A. Fox · San Francisco, US
• Ivica Fucek · Hattersheim, DE
• Jeanmarie GUENOT · San Francisco, US
• Stefan Knackmuss · Plankstadt, DE
• Lori Kunkel · San Francisco, US
• Melvyn Little · Büdelsdorf, DE
• Vera Molkenthin · Tännesberg, DE
• Erich Rajkovic · Schriesheim, DE
• Uwe Reusch · Maikammer, DE
• Claudia WALL · Zeven, DE
• Michael Weichel · Bischofsheim, DE
• Eugene Zhukovsky · West Hollywood, US

Key dates

• Filing date: Nov 10, 2015
• Grant date: Oct 31, 2017
• Expiry date: Nov 10, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).